The orally bioavailable IRAK-4 inhibitor, emavusertib, is emerging as an efficacious treatment in the therapeutic armamentarium against B-cell NHL and MDS/AML. The gene discussed is IRAK4; the disease is B-cell non-Hodgkin lymphoma.